Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials

Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials

Abstract Background *CoNivolumab, an immune checkpoint inhibitor, has shown promise in treating advanced unresectable gastric and gastroesophageal junction cancer. This meta-analysis aims to evaluate the efficacy and safety of Nivolumab, alone and in combination with chemotherapy, in this patient po...

Full description

Saved in:
Bibliographic Details
Main Authors: Xinming Lei, Weimin Huo, Tian Xu, Jianguang Xu, Maoning Liu, Chengjiang Liu, Zhangyuan Gu
Format: Article
Language:English
Published: BMC 2024-11-01
Series:BMC Gastroenterology
Subjects:
Nivolumab
Gastric cancer
Gastroesophageal junction cancer
Meta-analysis
Immunotherapy
Adverse events
Online Access:https://doi.org/10.1186/s12876-024-03508-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12876-024-03508-0

Similar Items